Skip to main content
Premium Trial:

Request an Annual Quote

Michael Barber, Rich Keffer

GE has appointed Michael Barber as chief technology officer of GE Healthcare and a vice president of technology, diagnostic imaging. He has been the general manager of technology since May 2005 and has been with GE since 1981. He held other positions in GE Healthcare, including general manager for components engineering and general manager for global components operations.
Barber received his bachelors' degree in electrical engineering from the Milwaukee School of Engineering.

Sigma-Aldrich this week said that it has tabbed Rich Keffer as corporate vice president, general counsel and secretary, effective Aug. 28.
Keffer most recently served as general counsel for D&K Healthcare, which was acquired in 2005 by McKesson. Overall, he has 25 years of corporate legal experience at a variety of global public companies in the consumer products, chemical, and pharmaceutical industries, Sigma said.
Keffer earned a JD from Washington University School of Law and a BA in economics from Greenville College.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.